Literature DB >> 16547320

Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

R P Singh1, C Patel, J E Sears.   

Abstract

BACKGROUND/AIMS: Recent studies on the treatment of acute subretinal macular haemorrhage have shown that the volume of the clot and the time to evacuation have strong prognostic factors for visual outcome. A novel technique for surgical evacuation of these lesions involves direct injection of tissue plasminogen activator (t-PA) into the haematoma using pars plana vitrectomy. The aim of this study was to evaluate the clinical outcomes of this recently described procedure.
METHODS: 17 consecutive patients with subretinal macular haemorrhages caused by age related macular degeneration were enrolled. Patient demographics, acuities, and fluorescein angiograms were obtained for all evaluations. All patients underwent complete three port pars plana vitrectomy to enable direct cannulation of the subretinal space and injection of 48 mug of t-PA, partial fluid-air exchange, 1 hour face up supine positioning postoperatively, followed by upright positioning overnight.
RESULTS: 88% of patients within the study had stabilisation or improvement of visual acuity. Nine patients had total clearing of the macular haemorrhage and eight patients had subtotal clearing. Two patients had recurrence of the haemorrhage after the procedure and one patient underwent repair for retinal detachment. Occult lesions demonstrated similar outcomes to classic or predominately classic lesions. Nine patients required no therapy after the study to treat subfoveal neovascularisation.
CONCLUSIONS: This study represents one of the largest case series to date showing that direct injection of subretinal t-PA with air-fluid exchange only and no intraoperative clot lysis period can have favourable results.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547320      PMCID: PMC1856980          DOI: 10.1136/bjo.2005.085001

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  26 in total

1.  Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat.

Authors:  J D Benner; L S Morse; C A Toth; M B Landers; L M Hjelmeland
Journal:  Arch Ophthalmol       Date:  1991-12

2.  Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration.

Authors:  R L Avery; S Fekrat; B S Hawkins; N M Bressler
Journal:  Retina       Date:  1996       Impact factor: 4.256

3.  Variations in the clinical course of submacular hemorrhage.

Authors:  M H Berrocal; M L Lewis; H W Flynn
Journal:  Am J Ophthalmol       Date:  1996-10       Impact factor: 5.258

4.  Submacular hemorrhage removal.

Authors:  J I Lim; C Drews-Botsch; P Sternberg; A Capone; T M Aaberg
Journal:  Ophthalmology       Date:  1995-09       Impact factor: 12.079

5.  The use of intravitreal tissue plasminogen activator in the treatment of experimental subretinal hemorrhage in the pig model.

Authors:  D E Boone; H C Boldt; R D Ross; J C Folk; A E Kimura
Journal:  Retina       Date:  1996       Impact factor: 4.256

6.  Fibrin directs early retinal damage after experimental subretinal hemorrhage.

Authors:  C A Toth; L S Morse; L M Hjelmeland; M B Landers
Journal:  Arch Ophthalmol       Date:  1991-05

7.  Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage.

Authors:  H Lewis
Journal:  Am J Ophthalmol       Date:  1994-11-15       Impact factor: 5.258

8.  Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage.

Authors:  A P Moriarty; I L McAllister; I J Constable
Journal:  Eye (Lond)       Date:  1995       Impact factor: 3.775

9.  Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes.

Authors:  W D Irvine; M W Johnson; E Hernandez; K R Olsen
Journal:  Arch Ophthalmol       Date:  1991-05

10.  Tissue plasminogen activating factor assisted removal of subretinal hemorrhage.

Authors:  G A Peyman; N C Nelson; W Alturki; K J Blinder; C L Paris; U R Desai; C A Harper
Journal:  Ophthalmic Surg       Date:  1991-10
View more
  14 in total

Review 1.  Clinical characteristics and current treatment of age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Ivana K Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-03       Impact factor: 6.915

2.  Intrasurgical assessment of subretinal tPA injection for submacular hemorrhage in the PIONEER study utilizing intraoperative OCT.

Authors:  Justis P Ehlers; Daniel S Petkovsek; Alex Yuan; Rishi P Singh; Sunil K Srivastava
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-03       Impact factor: 1.300

3.  The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.

Authors:  Matthias Lüke; Kai Januschowski; Max Warga; Julia Beutel; Martin Leitritz; Faik Gelisken; Salvatore Grisanti; Toni Schneider; Christoph Lüke; Karl Ulrich Bartz-Schmidt; Peter Szurman
Journal:  Br J Ophthalmol       Date:  2007-03-23       Impact factor: 4.638

4.  Age-related macular degeneration: current treatments.

Authors:  Jean Pierre Hubschman; Shantan Reddy; Steven D Schwartz
Journal:  Clin Ophthalmol       Date:  2009-06-02

5.  Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.

Authors:  Luis Arias; Jordi Monés
Journal:  Clin Ophthalmol       Date:  2010-02-18

6.  Treatment of massive subretinal hematoma associated with age-related macular degeneration using vitrectomy with intentional giant tear.

Authors:  Eisuke Isizaki; Seita Morishita; Takaki Sato; Masanori Fukumoto; Hiroyuki Suzuki; Teruyo Kida; Mari Ueki; Tsunehiko Ikeda
Journal:  Int Ophthalmol       Date:  2015-07-28       Impact factor: 2.031

7.  Visual outcome after vitreous, sub-internal limiting membrane, and/or submacular hemorrhage removal associated with ruptured retinal arterial macroaneurysms.

Authors:  Hideo Nakamura; Kazuhisa Hayakawa; Shoichi Sawaguchi; Takeshi Gaja; Noriyoshi Nagamine; Kodo Medoruma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-12-11       Impact factor: 3.117

8.  Branch retinal vein occlusion-associated subretinal hemorrhage.

Authors:  Yuki Muraoka; Akitaka Tsujikawa; Tomoaki Murakami; Ken Ogino; Kazuaki Miyamoto; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2013-03-19       Impact factor: 2.447

9.  Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm.

Authors:  Elsbeth J T van Zeeburg; Matteo G Cereda; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-04       Impact factor: 3.117

Review 10.  Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.

Authors:  Paris Tranos; Georgios N Tsiropoulos; Spyridon Koronis; Athanasios Vakalis; Solon Asteriadis; Panagiotis Stavrakas
Journal:  Int Ophthalmol       Date:  2021-07-30       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.